Clinical Trials Logo

Clinical Trial Summary

This single arm study will assess patient preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis. Patients currently on a daily or weekly regimen of bisphosphonate therapy (alendronate or risedronate) will answer a questionnaire to identify patients who may benefit from a monthly Bonviva regimen. Eligible patients will then discontinue their present bisphosphonate treatment, and switch to monthly Bonviva 150mg po. At the beginning and end of Bonviva treatment, all patients will complete an Osteoporosis Patient Satisfaction Questionnaire. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00545779
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Completed
Phase Phase 4
Start date December 2006
Completion date July 2010

See also
  Status Clinical Trial Phase
Completed NCT01224717 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women Phase 1
Completed NCT00551174 - A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment Phase 4
Completed NCT00984893 - Intra-venous Zoledronic Acid Once Yearly N/A
Withdrawn NCT01826656 - Bone Healing in Healthy and Post-menopausal Osteoporotic Women N/A
Completed NCT00718861 - 3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs Phase 3
Completed NCT00081653 - A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva Phase 4
Completed NCT00503113 - A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. Phase 4
Completed NCT00150969 - Vitamin K Supplementation in Post-Menopausal Osteopenia Phase 3
Completed NCT03432533 - A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis Phase 3
Completed NCT00533650 - Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005) Phase 2
Active, not recruiting NCT01232647 - Vitamin K as Additive Treatment in Osteoporosis Phase 2/Phase 3
Completed NCT00666627 - Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects Phase 2